Profound Medical said new CAPTAIN trial results showed whole-gland TULSA ablation outperformed robotic radical prostatectomy on penile length preservation at one month. The company described the difference as statistically significant, highlighting a quality-of-life measure that can matter to men weighing prostate cancer treatment options.
The update centers on a comparison between robotic radical prostatectomy and TULSA, a minimally invasive ablation approach delivered with MRI guidance. Based on the company information provided, Profound’s flagship TULSA-PRO platform is designed for interventional MRI procedures, positioning the technology as an alternative to whole-gland surgery in selected prostate cases.
While the announcement focuses on the early penile length finding, it does not provide the full range of trial outcomes in the available excerpt. That means the headline result is best understood as one specific measure from the CAPTAIN study rather than a complete picture of all clinical endpoints.
Profound Medical, a commercial-stage medical device company, framed the CAPTAIN trial data as support for the potential benefits of MRI-guided prostate ablation. The result is likely to draw attention from clinicians and patients following less invasive prostate cancer treatments and how they compare with robotic prostatectomy on functional outcomes.
